A Dose of NovoSeven  rFVIIa In Management of DIC with Sepsis.

Madhusudan R. Jaju; S.Vijay Mohan; Sirisha Rao Muttavarapu; Siddharth Bandla; V.Chandra Sekhar; Mohammed Faisal; Varaprasad; Shashank Kumar Srivastav; Abdul Ghani Siddiqui

Volume : VI, Issue : V, May - 2017

A Dose of NovoSeven rFVIIa In Management of DIC with Sepsis.

Madhusudan R. Jaju, S. Vijay Mohan, Sirisha Rao Muttavarapu, Siddharth Bandla, V. Chandra Sekhar, Mohammed Faisal, Varaprasad, Shashank Kumar Srivastav, Abdul Ghani Siddiqui

Abstract :

NovoSeven� is recombinant human coagulation Factor VIIa (rFVIIa), intended for promoting hemostasis by activating the extrinsic pathway of the coagulation cascade. NovoSeven is a vitamin K–dependent glycoprotein consisting of 406 amino acid residues (MW 50 K Dalton). NovoSeven is structurally similar to human plasma–derived Factor VIIa. We report a case of 32–year–old female patient of P2L2 who had oozing from suture line and per vaginal bleeding post–emergency LSCS. She was managed with massive blood transfusion of total 10–units cryoprecipitate, 6–units PRBC, 8–units FFP, 4–units RDP and 5–SDP and 1 dose of Injection Factor VII 4 mg given 90mcg/kg – NOVOSEVEN (4500 mcg)– 4 mg bolus IV. Following which she recovered better with her parameters under normal range.